Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice

Neurotoxicity Research

Volumn 19, Issue 1, 2011, Pages 73-80

  Romão, Pedro R T ^a   Lemos, Joelson C ^a   Moreira, Jeverson ^a   De Chaves, Gisele ^a   Moretti, Morgana ^a   Castro, Adalberto A ^a   Andrade, Vanessa M ^a   Boeck, Carina R ^a   Quevedo, João ^a   Gavioli, Elaine C ^a,b  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Animal behavior; Antiretroviral drugs; Efavirenz; Elevated plus maze test; Inhibitory avoidance task; Nevirapine; Object recognition task

Indexed keywords

EFAVIRENZ; NEVIRAPINE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; COGNITION; CONTROLLED STUDY; EMOTION; FORCED SWIMMING TEST; LOCOMOTION; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL;

ANIMALS; ANTI-HIV AGENTS; ANXIETY; BENZOXAZINES; COGNITION; EXPLORATORY BEHAVIOR; MALE; MICE; NEVIRAPINE;

ANIMALIA; MUS;

EID: 78650565431     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9141-y     Document Type: Article

References (40)

1. R Andreatini LF Bacellar 1999 The relationship between anxiety and depression in animal models: a study using the forced swimming test and elevated plus-maze Braz J Med Biol Res 32 1121 1126 1:STN:280:DyaK1MzpsV2gsA%3D%3D 10.1590/S0100-879X1999000900011 10464389
2. H Anisman Z Merali 2002 Cytokines, stress, and depressive illness Brain Behav Immun 16 513 524 1:CAS:528:DC%2BD38XotFSgtbw%3D 10.1016/S0889-1591(02) 00009-0 12401465
3. C Anthonypillai RN Sanderson JE Gibbs SA Thomas 2004 The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig J Pharmacol Exp Ther 308 912 920 1:CAS:528:DC%2BD2cXhvVWntLo%3D 10.1124/jpet.103.060210 14634041
4. G Arendt D Nocker HJ von Giesen T Nolting 2007 Neuropsychiatric side effects of efavirenz therapy Expert Opin Drug Saf 6 147 154 1:CAS:528: DC%2BD2sXjtFKns7k%3D 10.1517/14740338.6.2.147 17367260
5. M Bickel C Stephan C Rottmann A Carlebach A Haberl IM Kurowsk S Staszewski 2005 Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis Scand J Infect Dis 37 520 522 10.1080/00365540410020901 16012018
6. Brazil, Brazilian Ministry of Health, Division of Health Surveillance, National Program on STD/AIDS (2008) Recommendations on antiretroviral therapy in HIV-infected adults - 2008. Brazilian Ministry of Health, Brasília, 244 pp. Available: http://www.aids.gov.br/data/documents/storedDocuments/ %7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B762E0EBF-A859-4779-8A92- 704EB1F3B290%7D/consensoAdulto005c-2008montado.pdf. Accessed 12 May 2009
7. E Choleris AW Thomas M Kavaliers FS Prato 2001 A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field Neurosci Biobehav Rev 25 235 260 1:CAS:528:DC%2BD3MXjvV2ntbw%3D 10.1016/S0149-7634(01)00011-2 11378179
8. JF Cryan A Markou I Lucki 2002 Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol Sci 23 238 245 1:CAS:528:DC%2BD38XjsVWjsbo%3D 10.1016/S0165-6147(02)02017-5 12008002
9. MM de Maat R ter Heine EC van Gorp JW Mulder AT Mairuhu JH Beijnen 2003 Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment AIDS 17 2209 2214 10.1097/00002030-200310170-00009 14523278
10. E Dere JP Huston MA De Souza Silva 2007 The pharmacology neuroanatomy and neurogenetics of one-trial object recognition in rodents Neurosci Biobehav Rev 31 673 704 1:CAS:528:DC%2BD2sXkvFOmtLY%3D 10.1016/j.neubiorev.2007.01.005 17368764
11. CR Fumaz JA Munõz-Moreno J Moltó E Negredo MJ Ferrer G Sirera N Pérez-Alvarez G Gómez D Burger B Clotet 2005 Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence J Acquir Immune Defic Syndr 38 560 565 10.1097/01.qai.0000147523.41993.47 15793366
12. JE Gibbs Z Gaffen SA Thomas 2006 Nevirapine uptake into the central nervous system of the Guinea pig: an in situ brain perfusion study J Pharmacol Exp Ther 317 746 751 1:CAS:528:DC%2BD28XktFamu78%3D 10.1124/jpet.105.098459 16424147
13. PE Gold 1986 The use of avoidance training in studies of modulation of memory storage Behav Neural Biol 46 87 98 1:STN:280:DyaL283mvV2juw%3D%3D 10.1016/S0163-1047(86)90927-1 3015121
14. F Gutiérrez A Navarro S Padilla R Antón M Masiá J Borrás A Martín-Hidalgo 2005 Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring Clin Infect Dis 41 1648 1653 10.1086/497835 16267739
15. DW Haas HJ Ribaudo RB Kim C Tierney GR Wilkinson RM Gulick DB Clifford T Hulgan C Marzolini EP Acosta 2004 Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study AIDS 18 2391 2400 1:CAS:528:DC%2BD2cXhtFGhtbvI 15622315
16. I Izquierdo JH Medina 1997 Memory Formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures Neurobiol Learn Mem 68 285 316 1:CAS:528:DyaK2sXnslOhsro%3D 10.1006/nlme.1997.3799 9398590
17. I Izquierdo ME Pereira JH Medina 1990 Benzodiazepine receptor ligand influences on acquisition: suggestion of an endogenous modulatory mechanism mediated by benzodiazepine receptors Behav Neural Biol 54 27 41 1:CAS:528:DyaK3cXls1GhtL0%3D 10.1016/0163-1047(90)91221-V 1974134
18. CR Jost CE Van Der Zee HJ In't Zandt F Oerlemans M Verheij F Streijger J Fransen A Heerschap AR Cools B Wieringa 2002 Creatine kinase B-driven energy transfer in the brain is important for habituation and spatial learning behaviour, mossy fibre field size and determination of seizure susceptibility Eur J Neurosci 15 1692 1706 10.1046/j.1460-9568.2002.02001.x 12059977
19. W Lewis CP Haase YK Miller B Ferguson T Stuart T Ludaway J McNaught R Russ J Steltzer R Santoianni R Long G Fiermonte F Palmieri 2005 Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS Lab Invest 85 972 981 1:CAS:528:DC%2BD2MXhtVGmtL%2FE 10.1038/labinvest.3700301 15951836
20. RG Lister 1987 The use of a plus-maze to measure anxiety in the mouse Psychopharmacology 92 180 185 1:CAS:528:DyaL2sXktlejurc%3D 3110839
21. R McArthur F Borsini 2006 Animal models of depression in drug discovery: a historical perspective Pharmacol Biochem Behav 84 436 452 1:CAS:528: DC%2BD28XptFCiu7Y%3D 10.1016/j.pbb.2006.06.005 16844210
22. SM O'Mahony AM Myint H Steinbusch BE Leonard 2005 Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats Neuroimmunomodulation 12 293 298 10.1159/000087107 16166808
23. E Phillips S Mallal 2007 Drug hypersensitivity in HIV Curr Opin Allergy Clin Immunol 7 324 330 10.1097/ACI.0b013e32825ea68a 17620824
24. FJ Piacenti 2006 An update and review of antiretroviral therapy Pharmacotherapy 26 1111 1133 1:CAS:528:DC%2BD28XoslWkurw%3D 10.1592/phco.26.8. 1111 16863488
25. RD Porsolt M Le Pichon M Jalfre 1977 Depression: a new animal model sensitive to antidepressant treatments Nature 266 730 732 1:CAS:528: DyaE2sXkvFGhur4%3D 10.1038/266730a0 559941
26. GZ Réus SS Valvassori RA Machado MR Martins EC Gavioli J Quevedo 2008 Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats Naunyn Schmiedebergs Arch Pharmacol 376 295 300 10.1007/s00210-007-0235-x 18075734
27. TA Rihs K Begley DE Smith J Sarangapany A Callaghan M Kelly JJ Post J Gold 2006 Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study HIV Med 7 544 548 1:CAS:528:DC%2BD2sXhtFGgtw%3D%3D 10.1111/j.1468-1293.2006.00419.x 17105514
28. A Rivero JA Mira JA Pineda 2007 Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors J Antimicrob Chemother 59 342 346 1:CAS:528:DC%2BD2sXktlKgs7w%3D 10.1093/jac/dkl524 17255142
29. B Roca 2009 Adverse drug reactions to antiretroviral medication Front Biosci 14 1785 1792 1:CAS:528:DC%2BD1MXltFeis7o%3D 10.2741/3340 19273162
30. RJ Rodgers A Dalvi 1997 Anxiety, defense and the elevated plus-maze Neurosci Biobehav Rev 21 801 810 1:STN:280:DyaK1c%2FnslOmtg%3D%3D 10.1016/S0149-7634(96)00058-9 9415905
31. R Roesler R Walz J Quevedo F de-Paris SM Zanata E Graner I Izquierdo VR Martins RR Brentani 1999 Normal inhibitory avoidance learning and anxiety, but increased locomotor activity in mice devoid of PrP(C) Brain Res Mol Brain Res 71 349 353 1:CAS:528:DyaK1MXmslehurc%3D 10.1016/S0169-328X(99)00193-X 10521590
32. N Sacktor RH Lyles R Skolasky C Kleeberger OA Selnes EN Miller JT Becker B Cohen JC McArthur 2001 HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998 Neurology 56 257 260 1:STN:280:DC%2BD3M7pt1yhuw%3D%3D 11160967
33. A Saitoh E Sarles E Capparelli F Aweeka A Kovacs SK Burchett A Wiznia S Nachman T Fenton SA Spector 2007 CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children AIDS 21 2191 2199 1:CAS:528:DC%2BD2sXhtl2ntLzM 10.1097/QAD.0b013e3282ef9695 18090046
34. EL Streck G Scaini GT Rezin J Moreira CM Fochesato PRT Romão 2008 Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity Metab Brain Dis 23 485 492 1:CAS:528:DC%2BD1cXht12ku7fM 10.1007/s11011-008-9109-2 18815873
35. KT Tashima AM Caliendo M Ahmad JM Gormley WD Fiske JM Brennan TP Flanigan 1999 Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy J Infect Dis 180 862 864 1:CAS:528: DyaK1MXmtVyktLo%3D 10.1086/314945 10438381
36. GJ Treisman AI Kaplin 2002 Neurologic and psychiatric complications of antiretroviral agents AIDS 16 1201 1215 1:CAS:528:DC%2BD38XlsFOrtbY%3D 10.1097/00002030-200206140-00002 12045485
37. RM van Praag EC van Weert RP van Heeswijk XJ Zhou JP Sommadossi S Jurriaans JM Lange RM Hoetelmans JM Prins 2002 Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy Antimicrob Agents Chemother 46 896 899 10.1128/AAC.46.3.896-899.2002 11850283
38. HJ von Giesen H Köller A Theisen G Arendt 2002 Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients J Acquir Immune Defic Syndr 29 363 367
39. ME Wise K Mistry S Reid 2002 Drug points: neuropsychiatric complications of nevirapine treatment BMJ 324 879 10.1136/bmj.324.7342.879 11950737
40. HE Wynn RC Brundage CV Fletcher 2002 Clinical implications of CNS penetration of antiretroviral drugs CNS Drugs 16 595 609 1:CAS:528: DC%2BD38Xnt1arsbY%3D 10.2165/00023210-200216090-00002 12153332